XML 22 R7.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Preferred stock
Series X redeemable convertible preferred stock
Common stock
Underwriting agreement
Common stock
at-the-market offerings
Common stock
Additional paid-in capital
Underwriting agreement
Additional paid-in capital
at-the-market offerings
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive loss
Underwriting agreement
at-the-market offerings
Total
Beginning balance at Dec. 31, 2022 $ 96,398     $ 28     $ 632,512 $ (507,643) $ (79,000)     $ 221,216
Beginning balance (in shares) at Dec. 31, 2022 31,455     27,501,340                
Increase (Decrease) in Shareholders' Equity                        
Issuance of common stock upon the conversion of preferred stock $ (1,074)           1,074          
Issuance of common stock upon the conversion of preferred stock (in shares) (348)     57,910                
Issuance of common stock, net of issuance costs   $ 8 $ 5   $ 59,472 $ 28,493       $ 59,480 $ 28,498  
Issuance of common stock net of issuance costs (in shares)   8,253,895 4,738,606                  
Issuance of common stock upon exercise of options and warrants             420         420
Issuance of common stock upon exercise of options and warrants (in shares)       483,046                
Stock-based compensation expense             6,314         6,314
Unrealized gain on short-term investments                 79,000     79
Net Income (Loss)               (72,891)       (72,891)
Ending balance at Dec. 31, 2023 $ 95,324     $ 41     728,285 (580,534)       243,116
Ending balance (in shares) at Dec. 31, 2023 31,107     41,034,797                
Increase (Decrease) in Shareholders' Equity                        
Issuance of common stock, net of issuance costs   $ 10 $ 5   $ 117,162 $ 35,240       $ 117,172 $ 35,245  
Issuance of common stock net of issuance costs (in shares)   10,340,000 4,450,425                  
Issuance of common stock upon exercise of options and warrants       $ 1     4,784         4,785
Issuance of common stock upon exercise of options and warrants (in shares)       608,997                
Stock-based compensation expense             13,042         13,042
Unrealized gain on short-term investments                 163,000     163
Net Income (Loss)               (94,260)       (94,260)
Ending balance at Dec. 31, 2024 $ 95,324     $ 57     $ 898,513 $ (674,794) $ 163,000     $ 319,263
Ending balance (in shares) at Dec. 31, 2024 31,107     56,434,219